Melenor (Risedronate Sodium)

Risedronate sodium binds to hydroxyapatite at active bone remodeling sites. Once osteoclasts attach, the drug is taken up and inhibits farnesyl pyrophosphate synthase, a key enzyme for osteoclast function. This suppression reduces bone breakdown, allowing bone formation to predominate and improve overall bone strength.

The dose of Melenor is individualized by the prescribing healthcare professional based on the specific indication, patient characteristics, renal function, and concurrent therapies. Only a qualified prescriber should set the dosage regimen, and patients should follow the written prescription without alteration.

Safety of risedronate sodium in pregnancy and lactation has not been established. The product is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare provider is essential before use.

To request Melenor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

Melenor belongs to the bisphosphonate class, similar to alendronate or ibandronate. All share the same mechanism of inhibiting osteoclast-mediated bone resorption, but they differ in dosing frequency, potency, and specific safety profiles. Choice among them depends on patient preference, renal function, and physician assessment of risk‑benefit balance.

Melenor tablets should be stored at temperatures below 25 °C in their original container, protected from moisture and direct light. Keep the packaging tightly closed and out of reach of children. Do not store in bathrooms or near heat sources to maintain product stability.

Melenor is taken orally as a tablet with a full glass of plain water, preferably on an empty stomach at least 30 minutes before the first food, beverage, or other medication of the day. Patients should remain upright for at least 30 minutes after ingestion to reduce esophageal irritation.

The most serious adverse events linked to risedronate sodium include osteonecrosis of the jaw, atypical femur fractures, severe esophageal ulceration or erosion, and profound hypocalcemia. Prompt medical attention is required if symptoms such as jaw pain, unexplained thigh pain, difficulty swallowing, or muscle cramps develop.

Melenor is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), active esophageal disorders (e.g., strictures, ulcers), known hypersensitivity to risedronate or other bisphosphonates, and those unable to remain upright for 30 minutes after dosing. Caution is also advised for individuals on concomitant corticosteroids or anticoagulants.